2022
DOI: 10.1101/2022.12.10.519851
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India

Abstract: Lumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization against LSD in cattle. This study describes the evaluation of safety, immunogenicity and efficacy of a new live-attenuated LSD vaccine developed using an Indian field strain (LSDV/India/2019/Ranchi). The virus was attenuated by continuous … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 58 publications
0
1
0
Order By: Relevance
“…Salib and Osman started treatment studies in 2011 with the goal of reducing LSD consequences and saving lives. They were effective, utilizing a mix of medications that fight bacteria and inflammation, provide comfort, and treat infections [ 41 , 42 ]. They also advised to take anti-histaminic and non-steroidal anti-inflammatory medications.…”
Section: Control Measuresmentioning
confidence: 99%
“…Salib and Osman started treatment studies in 2011 with the goal of reducing LSD consequences and saving lives. They were effective, utilizing a mix of medications that fight bacteria and inflammation, provide comfort, and treat infections [ 41 , 42 ]. They also advised to take anti-histaminic and non-steroidal anti-inflammatory medications.…”
Section: Control Measuresmentioning
confidence: 99%